What is HC Wainwright's Estimate for CMPS FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Compass Pathways to a loss of $1.40 per share from a previously projected loss of $1.58, and maintained a Buy rating.
• The firm also forecast a FY2027 loss of $1.17 per share. Its FY2026 estimate is more pessimistic than the current full-year analyst consensus loss of $0.83 per share.
• Compass reported a quarterly loss of $0.31 per share, beating the consensus estimate of a $0.39 loss by $0.08. Analyst consensus on the stock is Moderate Buy, with an average price target of $23.14.

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) - Stock analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Compass Pathways in a report issued on Monday, November 9th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($1.40) per share for the year, up from their prior estimate of ($1.58). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Compass Pathways' current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Compass Pathways' Q4 2026 earnings at ($0.38) EPS, Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.31) EPS, Q3 2027 earnings at ($0.29) EPS, Q4 2027 earnings at ($0.25) EPS and FY2027 earnings at ($1.17) EPS.

Several other brokerages also recently commented on CMPS. Jefferies Financial Group reaffirmed a "buy" rating on shares of Compass Pathways in a research note on Monday. Morgan Stanley upped their price target on shares of Compass Pathways from $17.00 to $18.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Oppenheimer reissued an "outperform" rating and set a $20.00 price target on shares of Compass Pathways in a research report on Tuesday, November 3rd. BTIG Research reissued a "buy" rating and issued a $25.00 price target on shares of Compass Pathways in a report on Tuesday, November 3rd. Finally, B. Riley Financial raised their price target on shares of Compass Pathways from $17.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $23.14.

Compass Pathways Stock Up 0.8%

Shares of NASDAQ:CMPS opened at $9.25 on Wednesday. The stock has a market capitalization of $1.31 billion, a P/E ratio of -2.65 and a beta of 2.43. The stock's 50-day moving average price is $12.14 and its 200-day moving average price is $10.43. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.35. Compass Pathways has a 12-month low of $4.88 and a 12-month high of $15.87.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.08.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Vivo Capital LLC bought a new stake in Compass Pathways during the 1st quarter valued at approximately $1,106,000. Seven Fleet Capital Management LP grew its holdings in shares of Compass Pathways by 295.1% during the 1st quarter. Seven Fleet Capital Management LP now owns 158,021 shares of the company's stock worth $874,000 after acquiring an additional 118,021 shares during the period. Orbimed Advisors LLC purchased a new position in shares of Compass Pathways during the 1st quarter worth approximately $6,363,000. Eversept Partners LP bought a new position in shares of Compass Pathways in the 1st quarter worth approximately $3,749,000. Finally, Eagle Health Investments LP raised its position in shares of Compass Pathways by 35.6% in the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company's stock worth $11,394,000 after acquiring an additional 541,039 shares in the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.